Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Approves Cornerstone Therapeutics’ ANDA for Generic Tussionex Pennkinetic Product

FDAnews Drug Daily Bulletin

July 3, 2012 | Vol. 9 No. 130

FDA Approves Cornerstone Therapeutics’ ANDA for Generic Tussionex Pennkinetic Product

Cornerstone Therapeutics announced that the FDA approved its abbreviated new drug application (ANDA) for a generic Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release suspension product.
MarketWatch

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

The Buzz FDA Studying Composite Score Effect On DTC Marketing FDA Hydrocodone Decision Delay Reflects Enforcement, Access Tensions Biosimilar Interchangeability Battle Moves to California

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.